The new era of siRNA therapy: Advances in cancer treatment

Zhuan Zhang; Miaorong Yu; Guoqing Hu; Yong Gan

doi:10.1002/ctm2.70363

Clinical and Translational Medicine ›› 2025, Vol. 15 ›› Issue (6) : e70363 DOI: 10.1002/ctm2.70363

INVITED LETTER

The new era of siRNA therapy: Advances in cancer treatment

Zhuan Zhang ¹
, Miaorong Yu ¹^,²
, Guoqing Hu ³
, Yong Gan ¹^,²^,⁴

Author information +

History +

PDF

Cite this article

Download citation ▾

Zhuan Zhang, Miaorong Yu, Guoqing Hu, Yong Gan. The new era of siRNA therapy: Advances in cancer treatment. Clinical and Translational Medicine, 2025, 15(6): e70363 DOI:10.1002/ctm2.70363

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Tang Q, Khvorova A. RNAi-based drug design: considerations and future directions. Nat Rev Drug Discov. 2024; 23(5): 341-364.

[2]	Xie X, Yu T, Li X, et al. Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials. Signal Transduct Target Ther. 2023; 8(1): 1-71.

[3]	Ahn I, Kang CS, Han J. Where should siRNAs go: applicable organs for siRNA drugs. Exp Mol Med. 2023; 55(7): 1283-1292.

[4]	Xiao B, Wang S, Pan Y, et al. Development, opportunities, and challenges of siRNA nucleic acid drugs siRNA. Mol Ther—Nucleic Acids. 2025; 36(1): 102437.

[5]	Winkle M, El-Daly SM, Fabbri M, Calin GA. Noncoding RNA therapeutics—challenges and potential solutions. Nat Rev Drug Discov. 2021; 20(8): 629-651.

[6]	Cao J, Lv G, Wei F. Engineering exosomes to reshape the immune microenvironment in breast cancer: molecular insights and therapeutic opportunities. Clin Transl Med. 2024; 14(4): e1645.

[7]	Zhuo Y, Luo Z, Zhu Z, et al. Direct cytosolic delivery of siRNA via cell membrane fusion using cholesterol-enriched exosomes. Nat Nanotechnol. 2024; 19(12): 1858-1868.

[8]	Li S, Topatana W, Juengpanich S, et al. Development of synthetic lethality in cancer: molecular and cellular classification. Signal Transduct Target Ther. 2020; 5(1): 1-14.

[9]	Ge M, Luo J, Wu Y, Shen G, Kuang X. The biological essence of synthetic lethality: bringing new opportunities for cancer therapy. MedComm—Oncol. 2024; 3(1): e70.

[10]	Petropoulos M, Karamichali A, Rossetti GG, et al. Transcription-replication conflicts underlie sensitivity to PARP inhibitors. Nature. 2024; 628(8007): 433-441.

[11]	Thompson NA, Ranzani M, van der Weyden L, et al. Combinatorial CRISPR screen identifies fitness effects of gene paralogues. Nat Commun. 2021; 12(1): 1302.

[12]	Fuentes-Antrás J, Bedard PL, Cescon DW. Seize the engine: emerging cell cycle targets in breast cancer. Clin Transl Med. 2024; 14(1): e1544.

[13]	Gelot C, Kovacs MT, Miron S, et al. Polθ is phosphorylated by PLK1 to repair double-strand breaks in mitosis. Nature. 2023; 621(7978): 415-422.

[14]	Afrin H, Geetha Bai R, Kumar R, Ahmad SS, Agarwal SK, Nurunnabi M. Oral delivery of RNAi for cancer therapy. Cancer Metastasis Rev. 2023; 42(3): 699-724. Published online March 27, 2023.

[15]	Wei Y, Li X, Lin J, et al. Oral delivery of siRNA using fluorinated, small-sized nanocapsules toward anti-inflammation treatment. Adv Mater. 2023; 35(11): 2206821.

[16]	Yu M, Qin J, Liu X, et al. Evaluating the oral delivery of GalNAc-conjugated siRNAs in rodents and non-human primates. Nucleic Acids Res. 2024; 52(10): 5423-5437.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.